Citi's Downward Revision of GlaxoSmithKline Share Target Reflects Concerns Over Arexvy Vaccine Outlook
Friday, 5 July 2024, 05:29
Citi Reduces GlaxoSmithKline Share Target
In a notable move, Citi has lowered the share target for GlaxoSmithKline, citing specific reasons related to the Arexvy vaccine.
Concerns Over Arexvy Vaccine Prospects
- The decision reflects doubts surrounding the efficacy and market potential of the Arexvy vaccine.
- Investors are re-evaluating their positions in light of this revised target.
The shift in perspective by Citi underscores the importance of monitoring vaccine developments and their impact on pharmaceutical companies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.